Professor Ashfaq Shuaib, Director of Stroke Services at the University of Alberta Medical Center, and Principal Investigator of the SENTIS trial commented; "The SENTIS trial will provide the safety and efficacy data which stroke neurologists demand for adoption of a new stroke therapy: randomized, controlled data with a 90 day neurological endpoint. CoAxia has conducted this study at the highest level, and I am confident that the quality of the data, if the trial proves positive, will allow clinical adoption of this exciting new technology."
Lorinda Austin, Vice President of Clinical Affairs commented, "The SENTIS trial is a collaboration between CoAxia and stroke researchers from the US, Canada, Europe and Israel. Completion of enrollment of 515 patients is a key milestone for the trial. It indicates the worldwide clinical interest in the technology, and it signals our new focus: to complete patient data collection and determine our safety and efficacy profile."
Andrew M. Weiss, President and CEO commented, "CoAxia has invested more than 4 years and over $40M in the SENTIS trial, and we are excited about the ability to determine the safety and efficacy outcomes of the SENTIS trial later this year. If positive, we will have plans in place to submit our PMA to the FDA as well as initiate commercialization in Europe and around the world."
CoAxia, Inc. is a venture-backed, privately held, clinical-stage company focused on providing perfusion augmentation therapies that improve outcomes for patients with cerebral ischemia r
|SOURCE CoAxia, Inc.|
Copyright©2010 PR Newswire.
All rights reserved